THE ROLE OF PHARMACOGENETICS IN INDIVIDUAL RESPONSE TO ANTIPARKINSONIAN DRUGS

Simple item page
dc.contributor.authorBaran, Ahmet Hüsamettin
dc.date.accessioned2025-03-23T19:17:18Z
dc.date.available2025-03-23T19:17:18Z
dc.date.issued2022
dc.departmentSinop Üniversitesi
dc.description.abstractObjective: Parkinson’s disease, the second most common neurodegenerative disorder after Alzheimer’s, is a progressive neurodegenerative disease characterized by tremor, rigidity, bradikinesis and postural instability. Environmental and genetic factors contribute to the pathophysiology of this disease. The pioneer of dopamine, L-DOPA, remains the gold standard of pharmacotherapy. Although current therapeutic options are clinically beneficial, since parkinson’s disease is a progressive disorder, all drugs used in treatment decline over time and increase in side effects. Result and Discussion: Recent studies have shown that responses to antiparkinsonian drugs and their side effects exhibit significant interpersonal variability. Pharmacogenetics is a rapidly evolving and very promising field of research aiming to identify genetic markers associated with drug response. Studies in pharmacogenetics have shown that interpersonal genetic differences largely determine the response to drugs used to treat parkinson’s disease. Data obtained in this area will not only have the potential to present valuable therapeutic strategies for antiparkinson treatment, but also increase the probability of successful drug discovery. In this article, compiled studies to identify the role of genetic polymorphisms in better describing the variability in response to antiparkinson therapy and optimizing the pharmacotherapy of parkinson’s disease. © 2022 University of Ankara. All rights reserved.
dc.identifier.doi10.33483/jfpau.994367
dc.identifier.endpage536
dc.identifier.issn2564-6524
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85138946962
dc.identifier.scopusqualityQ3
dc.identifier.startpage523
dc.identifier.trdizinid1118936
dc.identifier.urihttps://doi.org/10.33483/jfpau.994367
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1118936
dc.identifier.urihttps://hdl.handle.net/11486/4296
dc.identifier.volume46
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorBaran, Ahmet Hüsamettin
dc.language.isotr
dc.publisherUniversity of Ankara
dc.relation.ispartofAnkara Universitesi Eczacilik Fakultesi Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20250323
dc.subjectdopamine
dc.subjectParkinson's disease
dc.subjectpharmacogenetics
dc.subjectpolymorphism
dc.titleTHE ROLE OF PHARMACOGENETICS IN INDIVIDUAL RESPONSE TO ANTIPARKINSONIAN DRUGS
dc.title.alternativeANTİPARKİNSON İLAÇLARINA VERİLEN BİREYSEL YANITTA FARMAKOGENETİĞİN ROLÜ
dc.typeArticle

Files

Collections

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize